Posaconazole: a new broad-spectrum antifungal agent.

Douglas S Kwon, Eleftherios Mylonakis

Massachusetts General Hospital, Division of Infectious Diseases, 55 Fruit Street, Boston, MA 02114-2696, USA.

Expert opinion on pharmacotherapy 2007 Jun

filter terms:

The rising incidence of invasive fungal infections and the emergence of broader fungal resistance have led to the need for novel antifungal agents. Posaconazole is a new member of the triazole class of antifungals. It is available as an oral suspension and has a favorable toxicity profile, has demonstrated clinical efficacy in the treatment of oropharyngeal candidiasis and has shown promise as salvage therapy for invasive aspergillosis, zygomycosis, cryptococcal meningitis and a variety of other fungal infections. In addition, data from randomized controlled studies support its efficacy for use in prophylaxis of invasive fungal infections in patients who are severely immunocompromised. The wide spectrum activity of posaconazole in in vitro studies, animal models and preliminary clinical studies suggest that posaconazole represents an important addition to the antifungal armamentarium.

Citation

Douglas S Kwon, Eleftherios Mylonakis. Posaconazole: a new broad-spectrum antifungal agent. Expert opinion on pharmacotherapy. 2007 Jun;8(8):1167-78